{"disease":{"id":"growth","name":"growth"},"drugs":{"marketed":[{"drug_id":"osimertinib","indication_name":"Adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"ibrance","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibrance","generic_name":"Palbociclib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":88,"revenue":"4500","mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"abemaciclib","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verzenio","generic_name":"abemaciclib","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/CDK6)","drug_class":"Kinase inhibitor","quality_score":78,"revenue":"3700","mechanism":"Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression."},{"drug_id":"trastuzumab-deruxtecan","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enhertu","generic_name":"trastuzumab-deruxtecan","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":63,"revenue":"2900","mechanism":"Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells."},{"drug_id":"trastuzumab","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"trastuzumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 receptor, subdomain IV","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"2900","mechanism":"HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells."},{"drug_id":"olaparib","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynparza","generic_name":"olaparib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor [EPC]","quality_score":73,"revenue":"2600","mechanism":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP."},{"drug_id":"bevacizumab","indication_name":"Non-small cell lung cancer with mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"cemiplimab","indication_name":"Nonsmall cell lung cancer without mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Libtayo","generic_name":"CEMIPLIMAB","company_name":"Regeneron Pharmaceuticals ","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"","quality_score":64,"revenue":"1452","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"cemiplimab","indication_name":"Non-small cell lung cancer without mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Libtayo","generic_name":"CEMIPLIMAB","company_name":"Regeneron Pharmaceuticals ","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"","quality_score":64,"revenue":"1452","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"tucatinib","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tukysa","generic_name":"tucatinib","company_name":"Seagen","drug_phase":"marketed","molecular_target":"ERBB2/ERBB3","drug_class":"Kinase Inhibitor [EPC]","quality_score":59,"revenue":"463","mechanism":"Tukysa works by blocking the ERBB2/ERBB3 receptors, which are involved in the growth and spread of cancer cells."},{"drug_id":"tukysa","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tukysa","generic_name":"tukysa","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ERBB2/ERBB3","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"463","mechanism":"Tukysa blocks the activity of ERBB2 and ERBB3 proteins, which are involved in cancer cell growth and spread."},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of growth hormone deficiency in adults.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of adult-onset growth hormone deficiency.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of growth hormone deficiency in adults with a history of radiation therapy to the head.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of growth hormone deficiency in adults with a history of pituitary surgery.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"genotropin","indication_name":"Severe growth hormone deficiency in adulthood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnitrope","generic_name":"Somatropin","company_name":"Serono","drug_phase":"marketed","molecular_target":"Dimeric GH receptors on cell membranes of target tissues","drug_class":"Recombinant human growth hormone","quality_score":10,"revenue":"446","mechanism":"Somatropin binds dimeric GH receptors on target cells, inducing intracellular signaling and GH-dependent protein synthesis including IGF-1."},{"drug_id":"genotropin","indication_name":"Growth retardation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnitrope","generic_name":"Somatropin","company_name":"Serono","drug_phase":"marketed","molecular_target":"Dimeric GH receptors on cell membranes of target tissues","drug_class":"Recombinant human growth hormone","quality_score":10,"revenue":"446","mechanism":"Somatropin binds dimeric GH receptors on target cells, inducing intracellular signaling and GH-dependent protein synthesis including IGF-1."},{"drug_id":"lonapegsomatropin","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone (GH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Skytrofa","generic_name":"LONAPEGSOMATROPIN","company_name":"Ascendis Pharma Encocrinology Div A/S","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":"446","mechanism":"Skytrofa works by mimicking the natural growth hormone to stimulate growth in individuals with growth hormone deficiency."},{"drug_id":"tremelimumab","indication_name":"Non-small cell lung cancer, negative for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imjudo","generic_name":"TREMELIMUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"CTLA-4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":62,"revenue":"400","mechanism":"Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth."},{"drug_id":"afatinib","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gilotrif","generic_name":"afatinib","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":68,"revenue":"400","mechanism":"Gilotrif works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow."},{"drug_id":"zolbetuximab","indication_name":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyloy","generic_name":"ZOLBETUXIMAB","company_name":"Astellas","drug_phase":"marketed","molecular_target":"","drug_class":"Claudin 18.2-directed Cytolytic Antibody [EPC]","quality_score":55,"revenue":"100","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction."},{"drug_id":"zolbetuximab","indication_name":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyloy","generic_name":"ZOLBETUXIMAB","company_name":"Astellas","drug_phase":"marketed","molecular_target":"","drug_class":"Claudin 18.2-directed Cytolytic Antibody [EPC]","quality_score":55,"revenue":"100","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction."},{"drug_id":"gleevec","indication_name":"Myelodysplastic/myeloproliferative diseases with re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"pd-0332991","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PD-0332991","generic_name":"pd-0332991","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2","drug_class":"PD-0332991, 125mg, 3 cycles","quality_score":null,"revenue":null,"mechanism":"PD-0332991, 125mg, 3 cycles"},{"drug_id":"tagrisso","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tagrisso","company_name":"Suzhou Genhouse Bio Co., Ltd.","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Cysteine--tRNA ligase, cytoplasmic, Dipeptidyl peptidase 1","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"omnitrope","indication_name":"Growth retardation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omnitrope","company_name":"Sandoz","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"omnitrope","indication_name":"Severe growth hormone deficiency in adulthood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omnitrope","company_name":"Sandoz","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-dkst","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OGIVRI","generic_name":"TRASTUZUMAB-DKST","company_name":"MYLAN GMBH","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"margetuximab-cmkb","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MARGENZA","generic_name":"MARGETUXIMAB-CMKB","company_name":"MACROGENICS INC","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A, Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"somapacitan-beco","indication_name":"Adult growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"lonapegsomatropin-tcgd","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone (GH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SKYTROFA","generic_name":"LONAPEGSOMATROPIN-TCGD","company_name":"ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S","drug_phase":"marketed","molecular_target":"growth hormone (GH) receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD."},{"drug_id":"tremelimumab-actl","indication_name":"Non-small cell lung cancer, negative for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"IMJUDO","generic_name":"TREMELIMUMAB-ACTL","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"dacomitinib-hydrate","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"dacomitinib hydrate","generic_name":"dacomitinib-hydrate","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho","quality_score":null,"revenue":null,"mechanism":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho"},{"drug_id":"lynparza","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lynparza","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"vizimpro","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"Dacomitinib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor","quality_score":75,"revenue":null,"mechanism":"Irreversible pan-HER kinase inhibitor targeting EGFR, HER2, HER4, and EGFR-activating mutations."},{"drug_id":"alpelisib","indication_name":"PIK3CA-related overgrowth spectrum (PROS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piqray","generic_name":"alpelisib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"PI3Kα","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Alpelisib inhibits PI3Kα, blocking Akt-signaling and preventing tumor growth and organ abnormalities in PROS disorders."},{"drug_id":"gefitinib","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iressa","generic_name":"gefitinib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Iressa blocks the epidermal growth factor receptor (EGFR) signaling pathway, preventing cancer cell growth and proliferation."},{"drug_id":"somatrogon","indication_name":"Growth failure due to inadequate secretion of endogenous growth hormone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ngenla","generic_name":"somatrogon","company_name":"Pfizer Ireland Pharmaceuticals","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Ngenla works by binding to the growth hormone receptor, mimicking the action of natural growth hormone."},{"drug_id":"sermorelin","indication_name":"Diagnostic Test for Growth Hormone Secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geref","generic_name":"sermorelin","company_name":"","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"sermorelin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ngenla","indication_name":"Growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ngenla","generic_name":"Somatrogon-Ghla","company_name":"Pfizer Ireland Pharmaceuticals","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Ngenla works by binding to the growth hormone receptor, mimicking the action of natural growth hormone to stimulate growth and development."},{"drug_id":"imatinib","indication_name":"Myelodysplastic/myeloproliferative diseases with re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"arginine","indication_name":"Diagnostic Test for Growth Hormone Secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"R-Gene 10","generic_name":"ARGININE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nitric oxide synthase, inducible","drug_class":"arginine hydrochloride","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"trazimera","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"Trastuzumab-Qyyp","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 (c-erbB2) proto-oncogene transmembrane receptor protein","drug_class":"HER2/neu receptor antagonist monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity."},{"drug_id":"ngenla-somatrogon","indication_name":"Short stature associated with idiopathic growth hormone deficiency in pediatric patients 2 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ngenla-somatrogon","indication_name":"Short stature associated with other causes of growth hormone deficiency in pediatric patients 2 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dacomitinib","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"dacomitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vizimpro works by blocking the EGFR tyrosine kinase, a protein that helps cancer cells grow and survive."},{"drug_id":"somapacitan","indication_name":"Adult growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"chembl-chembl4650215","indication_name":"endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"INAVOLISIB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells."},{"drug_id":"herceptin","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Herceptin","company_name":"National Cancer Institute (NCI)","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-herceptin","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trastuzumab (Herceptin)","generic_name":"trastuzumab-herceptin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"gilotrif","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gilotrif","company_name":"Seoul St. Mary's Hospital","drug_phase":"discontinued","molecular_target":"Citron Rho-interacting kinase, Adenosine kinase, Casein kinase I isoform epsilon","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"somatropine","indication_name":"Growth retardation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"somatropine","company_name":"Sanofi","drug_phase":"phase_3","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"somatropine","indication_name":"Severe growth hormone deficiency in adulthood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"somatropine","company_name":"Sanofi","drug_phase":"phase_3","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"calcium-hydrogen-phosphate-dihydrate","indication_name":"Support Normal Growth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dibasic Calcium Phosphate Dihydrate","generic_name":"calcium hydrogen phosphate dihydrate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"panthenol","indication_name":"Eyelash growth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ReOrganic Eyelash Growth Boosting Serum","generic_name":"PANTHENOL","company_name":"LAON COMMERCE co ltd","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"lonapegsomatropin-tcgd","indication_name":"Pediatric Growth Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SKYTROFA","generic_name":"LONAPEGSOMATROPIN-TCGD","company_name":"ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S","drug_phase":"marketed","molecular_target":"growth hormone (GH) receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD."},{"drug_id":"lonapegsomatropin-tcgd","indication_name":"Adult Growth Hormone Deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SKYTROFA","generic_name":"LONAPEGSOMATROPIN-TCGD","company_name":"ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S","drug_phase":"marketed","molecular_target":"growth hormone (GH) receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD."},{"drug_id":"somapacitan-beco","indication_name":"Growth failure due to inadequate GH secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"somapacitan-beco","indication_name":"Short stature SGA without catch-up growth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"somapacitan-beco","indication_name":"Growth failure associated with Noonan syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"multivitamins","indication_name":"Support Normal Growth and Development","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"multivitamins","company_name":"Faculdade de Medicina do ABC","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin C [EPC]","quality_score":17,"revenue":null,"mechanism":null},{"drug_id":"somapacitan","indication_name":"Growth failure due to inadequate GH secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"somapacitan","indication_name":"Short stature, SGA without catch-up growth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"somapacitan","indication_name":"Growth failure associated with Noonan syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"somapacitan","indication_name":"Growth hormone deficiency in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"chembl-chembl4297830","indication_name":"Growth failure due to inadequate growth hormone secretion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SOMATROGON","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"minoxidil-5","indication_name":"Hair and beard regrowth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minoxidil 5 %","company_name":"Mohammed Abd El Mawgoud Amer","drug_phase":"marketed","molecular_target":"","drug_class":"Arteriolar Vasodilator [EPC]","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"minoxidil-5","indication_name":"Hair and beard regrowth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minoxidil 5 %","company_name":"Mohammed Abd El Mawgoud Amer","drug_phase":"marketed","molecular_target":"","drug_class":"Arteriolar Vasodilator [EPC]","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"enhertu","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enhertu","company_name":"Washington D.C. Veterans Affairs Medical Center","drug_phase":"marketed","molecular_target":"DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"iressa","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Iressa","company_name":"David Adelstein","drug_phase":"discontinued","molecular_target":"Citron Rho-interacting kinase, Ferrochelatase, mitochondrial, Mitogen-activated protein kinase 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"avastin","indication_name":"Non-small cell lung cancer with mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"margetuximab","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Margenza","generic_name":"MARGETUXIMAB","company_name":"Macrogenics Inc","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":55,"revenue":null,"mechanism":"Margenza works by blocking the HER2/neu receptor, which is overexpressed in certain breast cancer cells, to prevent them from growing and multiplying."},{"drug_id":"zirabev","indication_name":"Non-small cell lung cancer with mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"somatrogon","indication_name":"Growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ngenla","generic_name":"somatrogon","company_name":"Pfizer Ireland Pharmaceuticals","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Ngenla works by binding to the growth hormone receptor, mimicking the action of natural growth hormone."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."}],"pipeline":[{"drug_id":"growth-hormone-replacement-therapy","indication_name":"Growth Hormone Deficiency","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Growth Hormone Replacement Therapy","generic_name":"growth-hormone-replacement-therapy","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"An observational study of patients who are commencing GH replacement as part of their routine NHS cl","quality_score":null,"revenue":null,"mechanism":"An observational study of patients who are commencing GH replacement as part of their routine NHS cl"}],"offLabel":[],"totalMarketed":79,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03072537","title":"CrescNet - Growth Monitoring Network","phase":"","overall_status":"RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"University of Leipzig","has_results":false},{"nct_id":"NCT07514377","title":"JiGenerations Health Cohort Study：Parental Exposure and Intergenerational Health in China","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"National Research Institute for Family Planning, China","has_results":false},{"nct_id":"NCT05142644","title":"IUGR; Cause and Relationship","phase":"","overall_status":"COMPLETED","enrollment_count":80000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03662178","title":"Investigating the Structured Use of Ultrasound Scanning for Fetal Growth","phase":"","overall_status":"RECRUITING","enrollment_count":56000,"lead_sponsor_name":"Oxford University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT06758622","title":"Analysis on the Health of Newborns in Three Hospitals, 2008-2024","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40000,"lead_sponsor_name":"HOSPITAL GINECO OBSTETRICO ISIDRO AYORA","has_results":false},{"nct_id":"NCT06653374","title":"Perinatal Conditions Influencing Morbidity, Mortality, and Medical Care in Newborns","phase":"","overall_status":"COMPLETED","enrollment_count":26000,"lead_sponsor_name":"HOSPITAL GINECO OBSTETRICO ISIDRO AYORA","has_results":false},{"nct_id":"NCT01009905","title":"An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)","phase":"","overall_status":"COMPLETED","enrollment_count":22960,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT00960128","title":"Observational Prospective Study on Patients Treated With Norditropin®","phase":"","overall_status":"COMPLETED","enrollment_count":21249,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02769975","title":"Evaluation of Children With Endocrine and Metabolic-Related Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT03398629","title":"Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT06074601","title":"MIRACLE of LIFE Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Mirvie","has_results":false},{"nct_id":"NCT04766866","title":"sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.","phase":"NA","overall_status":"RECRUITING","enrollment_count":9132,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT03099837","title":"Tongji Maternal and Child Health Cohort","phase":"","overall_status":"UNKNOWN","enrollment_count":8649,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT06339606","title":"Pregnancy Repository","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Sunnybrook Health Sciences Centre","has_results":false},{"nct_id":"NCT04345185","title":"Effects of Infant Egg Consumption on Child Health and Cognition Development","phase":"","overall_status":"COMPLETED","enrollment_count":5374,"lead_sponsor_name":"State University of New York at Buffalo","has_results":false},{"nct_id":"NCT05244785","title":"Health and Nutrition Survey on Shenzhen Children","phase":"","overall_status":"COMPLETED","enrollment_count":4500,"lead_sponsor_name":"Shenzhen Center for Chronic Disease Control","has_results":false},{"nct_id":"NCT05326191","title":"First-trimester Placental Ultrasound Study","phase":"","overall_status":"COMPLETED","enrollment_count":4000,"lead_sponsor_name":"Perspectum","has_results":false},{"nct_id":"NCT03955913","title":"A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations","phase":"","overall_status":"COMPLETED","enrollment_count":3679,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT00340002","title":"Fetal Anatomy by Three-Dimensional Ultrasound","phase":"","overall_status":"COMPLETED","enrollment_count":3650,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT07222423","title":"A Study of the Epidemiology and Hospital Management of Patients With PROS in France","phase":"","overall_status":"COMPLETED","enrollment_count":3605,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05576207","title":"BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3390,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT03297970","title":"Bogota School Children Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":3202,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT06115122","title":"PEPPI Study: Identification of Women at Risk for Placental Dysfunction","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Oulu University Hospital","has_results":false},{"nct_id":"NCT07029282","title":"The MOM-CARE Trial : Evaluating Antenatal and Postnatal MMSPlus for Improved Infant Birth and Growth Outcomes","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Aga Khan University","has_results":false},{"nct_id":"NCT05934318","title":"L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":2960,"lead_sponsor_name":"Liverpool School of Tropical Medicine","has_results":false},{"nct_id":"NCT05405400","title":"The Sugira Muryango Longitudinal & Spillover Study","phase":"","overall_status":"COMPLETED","enrollment_count":2932,"lead_sponsor_name":"Boston College","has_results":false},{"nct_id":"NCT03266198","title":"Fetal 3D Study (Fetal Body Composition and Volumes Study)","phase":"","overall_status":"COMPLETED","enrollment_count":2809,"lead_sponsor_name":"Katherine Grantz","has_results":false},{"nct_id":"NCT00912132","title":"The National Standard for Normal Fetal Growth","phase":"","overall_status":"COMPLETED","enrollment_count":2802,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT06037473","title":"The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg","phase":"","overall_status":"RECRUITING","enrollment_count":2600,"lead_sponsor_name":"Beijing Children's Hospital","has_results":false},{"nct_id":"NCT06323187","title":"Optimization of Cervical Collections in Pregnancy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2600,"lead_sponsor_name":"Dr. Sascha Drewlo","has_results":false},{"nct_id":"NCT05774912","title":"Development of Italian Fetal Growth Charts","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"IRCCS Burlo Garofolo","has_results":false},{"nct_id":"NCT04817878","title":"Cohort Construction for Preterm Infants With Growth Retardation and Its Influencing Factors","phase":"","overall_status":"UNKNOWN","enrollment_count":2400,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06096805","title":"Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shanghai First Maternity and Infant Hospital","has_results":false},{"nct_id":"NCT07015203","title":"The Combined First Trimester Screening","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Institute of Health Information and Statistics of the Czech Republic","has_results":false},{"nct_id":"NCT05606497","title":"OPtimal TIming of COrticosteroids in Early-onset Fetal Growth REstriction: the OPTICORE Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1800,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT04447248","title":"qCTG and Doppler Ultrasound in the Detection of Hypoxia Among FGR Fetuses","phase":"","overall_status":"COMPLETED","enrollment_count":1714,"lead_sponsor_name":"Orthogyn Medical Center, Bulgaria","has_results":false},{"nct_id":"NCT04438668","title":"Evaluation of the Safety and Performance of Centaflow","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1704,"lead_sponsor_name":"Centaflow","has_results":false},{"nct_id":"NCT03312049","title":"Aflatoxin Birth Cohort Study Nepal (AflaCohort)","phase":"","overall_status":"COMPLETED","enrollment_count":1675,"lead_sponsor_name":"Tufts University","has_results":false},{"nct_id":"NCT00001403","title":"Study of Proteus Syndrome and Related Congenital Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT03904914","title":"Thumb Ossification Composite Index (TOCI) to Predict Skeletal Maturity and Curve Progression in AIS","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04222998","title":"Home-based Growth Charts in Indonesia","phase":"NA","overall_status":"COMPLETED","enrollment_count":1487,"lead_sponsor_name":"Boston University","has_results":false},{"nct_id":"NCT05603793","title":"YoUng Adolescents' behaViour, musculoskeletAl heAlth, Growth & Nutrition","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1304,"lead_sponsor_name":"Hirabai Cowasji Jehangir Medical Research Institute","has_results":false},{"nct_id":"NCT03229629","title":"What Promotes Healthy Eating? The Roles of Information,Affordability,Accessibility,Gender, and Peers on Food Consumption","phase":"NA","overall_status":"COMPLETED","enrollment_count":1243,"lead_sponsor_name":"Cornell University","has_results":false},{"nct_id":"NCT03166332","title":"Improving Mothers for a Better PrenAtal Care Trial Barcelona","phase":"NA","overall_status":"COMPLETED","enrollment_count":1221,"lead_sponsor_name":"Hospital Clinic of Barcelona","has_results":false},{"nct_id":"NCT04316221","title":"Effects of Complementary Feeding of Eggs on Infant Development and Growth in Guatemala: The Saqmolo Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Academy of Nutrition and Dietetics","has_results":false},{"nct_id":"NCT03865628","title":"Ultrasound Evaluation of Fetal Hemodynamics and Perinatal Complications","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT04451109","title":"Dilapan-S®: A Multicenter US E-registry","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Medicem Technology s.r.o.","has_results":false},{"nct_id":"NCT03503799","title":"Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1191,"lead_sponsor_name":"North Eastern German Society of Gynaecological Oncology","has_results":false},{"nct_id":"NCT06797063","title":"Breastfeeding Education Support Tool","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1152,"lead_sponsor_name":"Thomas Jefferson University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}